PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma
Authors:
- Huaqi YinHYHuaqi Yin
- Ma YongkangMYMa Yongkang
- Guan BaoGBGuan Bao
- Zhao ShimingZSZhao Shiming
- He ChaohongHCHe Chaohong
- Yang TiejunYTYang Tiejun
Open Access
- 14 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (2) , e28591
Abstract
Rationale: Routine neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma prior to radical surgery is curative. With the increase in cancer immunotherapy, neoadjuvant immunotherapy has been used as an important complement to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Toripalimab is a recombinant, humanized IgG4 monoclonal antibody directed against programmed cell death protein 1 and received the first global approval for the treatment of unresectable or metastatic melanoma in China on December 17, 2018. Patient concerns and diagnosis: A 57-year-old man was admitted to our hospital because of hematuria for 1 week. The patient was diagnosed pathologically with muscle-invasive bladder urothelial carcinoma. Interventions and outcomes: The patient received neoadjuvant toripalimab combined with gemcitabine therapy. The patient showed partial response. Subsequently, radical cystectomy was performed. Lessons: Toripalimab combined with gemcitabine exhibited accurate antitumor activity and may be a promising novel neoadjuvant therapy for muscle-invasive urothelial carcinoma.Keywords
This publication has 14 references indexed in Scilit:
- Immunotherapy in Bladder Cancer: Current Methods and Future PerspectivesCancers, 2020
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432Annals of Oncology, 2019
- Toripalimab: First Global ApprovalDrugs, 2019
- Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of AgeDermatology, 2019
- Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsJournal of Hematology & Oncology, 2019
- Pembrolizumab for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerEuropean Urology, 2017
- In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomyCanadian Urological Association Journal, 2015
- Factors influencing post‐recurrence survival in bladder cancer following radical cystectomyBJU International, 2011
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010